Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: MRX-6

Latest Information Update: 19 May 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Morria Biopharmaceuticals
  • Developer Akari Therapeutics
  • Class Nonsteroidal anti-inflammatories; Skin disorder therapies
  • Mechanism of Action Arachidonic acid inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Allergic contact dermatitis; Atopic dermatitis

Most Recent Events

  • 17 Feb 2015 Efficacy data from a phase II trial in Atopic dermatitis released by Celsus Therapeutics
  • 13 Jan 2015 Celsus Therapeutics completes enrolment in its phase II trial for Atopic dermatitis (In adolescents, In children) in Israel (9173659; NCT02031445)
  • 12 Jan 2015 FDA approves IND application for MRX 6 in Atopic dermatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top